Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Microbot Medical (NASDAQ: MBOT) has announced the appointment of Professor Gerry O’Sullivan to its Scientific Advisory Board, enhancing its EU presence as it prepares for human clinical trials of the LIBERTY® Robotic System. With over 25 years of experience in interventional radiology, Professor O’Sullivan brings expertise in venous disease treatments. His involvement is expected to bolster innovation and execution of commercialization strategies. This comes amid increasing global interest in the LIBERTY system, designed to address the needs of interventional radiologists.
Microbot Medical Inc. (MBOT) has expanded its Scientific Advisory Board (SAB) with the appointment of Professor Mark W. Little, a distinguished academic leader from the UK. Professor Little will collaborate with other experts to enhance the regulatory and commercialization efforts for the LIBERTY Robotic System, the first single-use endovascular robotic device. Having significant experience in interventional radiology, he has previously participated in studies on the LIBERTY system and expressed confidence in its potential impact on the market. This addition signals a strengthening of the company’s clinical expertise and reinforces its strategic goals.
Microbot Medical (Nasdaq: MBOT) announced on March 13, 2023, that Dr. Stavros Spiliopoulos has joined its Scientific Advisory Board. As an internationally recognized interventional radiologist, Dr. Spiliopoulos's expertise will bolster the company's efforts to advance the LIBERTY® Robotic System towards regulatory approval and commercialization. His extensive experience in vascular interventional radiology and numerous awards further solidify his role. The addition reflects Microbot's ongoing strategy to enhance clinical awareness and establish centers of excellence in key growth markets in Europe and the Americas.
Microbot Medical (Nasdaq: MBOT) has announced that an abstract detailing the LIBERTY Robotic System will be presented at the Israeli Conference on Robotics on March 28, 2023. Dr. Eyal Morag, the company's Chief Medical Officer, will discuss the advantages of this single-use endovascular robotic system over traditional methods, highlighting reduced physician radiation exposure and physical stress. The presentation will include findings from animal feasibility studies showcasing performance and safety metrics. The conference serves as a major event for robotics advancements across various sectors, including healthcare.
Microbot Medical (Nasdaq: MBOT), recognized for developing the LIBERTY® Robotic System, has received a non-dilutive grant of 300,000 NIS from Israel's Ministry of Economy. This funding is part of the 'Smart Money' program aimed at enhancing the commercialization of its robotic system in the U.S. market. CFO Rachel Vaknin emphasized that this grant will boost marketing efforts and foster engagement with key stakeholders as the company approaches crucial regulatory and clinical phases. The grant may be repaid through future royalties from LIBERTY sales, marking a significant step toward increasing market awareness and anticipation for the product's launch.
Microbot Medical Inc. (MBOT) continues to promote its LIBERTY® Robotic System, the first single-use endovascular robotic system, ahead of its commercialization. At the upcoming Society of Interventional Radiologists (SIR) annual meeting from March 4-9 in Phoenix, Arizona, CEO Harel Gadot and other executives will engage with potential partners and leading interventional radiologists. The company aims to gather feedback to enhance user experience and improve patient care standards. Microbot specializes in micro-robotic technologies and aims to transform medical outcomes.